To investigate the incidence, haemodynamic alterations and 90-day mortality of acute kidney injury (AKI) in patients with cardiogenic shock. We assessed the utility of creatinine, urine output (UO) and cystatin C (CysC) definitions of AKI in prognostication. 
Introduction
Acute kidney injury (AKI) is characterized by an abrupt decrease in glomerular filtration rate and/or urine output (UO), and frequent among the critically ill, including patients with acute myocardial infarction and acute heart failure (AHF). 1 The Kidney Disease: Improving Global Outcomes (KDIGO) definition of AKI has replaced the previous RIFLE and AKIN criteria.
2 -5 The current AKI definition is based on an increase in plasma creatinine and/or a decrease in UO, and is divided into stages 1-3 depending on severity. 4 While even small increases in creatinine levels have been shown to be associated with poor prognosis, the UO criteria have not been extensively validated, 4 and conflicting results have been reported on whether the threshold of <0.5 mL/kg/h for 6 h is adequate for assessment of prognosis. 6 -8 In addition, cystatin C (CysC), an alternative marker of kidney function and risk stratification, 9 has been suggested to possess prognostic value both in AHF and AKI.
10 -12 Cardiogenic shock (CS) is a cardiac emergency and the most severe form of AHF. 13 ST-elevation myocardial infarction is the most common cause of CS, but the aetiological spectrum is broad and many other conditions may also lead to CS. Regardless of aetiology, CS is characterized by inadequate cardiac output leading to hypotension and signs and/or symptoms of end-organ hypoperfusion such as oliguria.
14 While venous congestion and reduced renal perfusion are considered the main mechanisms for impaired and worsening renal function in heart failure, 15 little is known about haemodynamic parameters, their evolution over time and relation to AKI in CS. The overall incidence, risk factors and mortality of AKI patients with critical illness, such as sepsis, are well characterized. 1, 16, 17 In contrast, data on AKI in the setting of CS are very scarce, reflecting a gap in knowledge.
The aim of this study was to describe the incidence of AKI using the contemporary KDIGO creatinine and UO criteria in a multinational prospective observational study on CS. In addition, we investigated the utility of CysC-based definitions of AKI (AKI CysC ). The associations of AKI with haemodynamic alterations and 90-day mortality were assessed. Finally, we explored a previously suggested stricter definition for UO-based AKI (AKI UO ) for mortality prediction. 7 
Methods

Study population
The CardShock study (ClinicalTrials.gov identifier: NCT01374867) is a prospective multicentre study, which recruited patients with CS at nine hospitals in eight European countries (Czech Republic, Denmark, Finland, Greece, Italy, Poland, Portugal, and Spain) between October 2010 and December 2012. 18 In addition to acute cardiac cause, the inclusion criteria were: systolic blood pressure (SBP) <90 mmHg for 30 min or need for vasopressor to maintain SBP >90 mmHg (in the absence of hypovolaemia or after adequate fluid challenge), and signs of organ hypoperfusion (any of the following: cold extremities, confusion or altered mental status, oliguria during the previous 6 h, or blood lactate >2 mmol/L). Patients had to be aged over 18 years and included in the study within the first 6 h of the detection of shock. The exclusion criteria were CS caused by ongoing haemodynamically significant arrhythmia and shock after cardiac or non-cardiac surgery. The distribution of specific aetiologies of CS in the study population has been previously described by Harjola et al. 18 Data collection, plasma sampling and acute kidney injury definitions Detailed medical history and patient characteristics were recorded. In addition, medical and invasive treatment procedures were registered. Urine output was recorded at 6, 12, 18, and 24 h; an average UO was calculated for consequent 6 h intervals dividing the total 6 h UO by body weight and time. Cardiac index (CI) was measured from patients with a pulmonary artery catheter (n = 61), and central venous pressure (CVP) from those with either a pulmonary artery catheter or a central venous catheter (n = 100). These data were collected at baseline (0 h), and 6, 12, 18, 24, 36, 48, 72 and 96 h; the mean values of measurements between 0-12 h, 18-24 h, 36-48 h, and 72-96 h were calculated for further analyses.
Serial plasma samples were collected at study baseline (0 h), and at 12, 24, 36 and 48 h. Of 178 patients with baseline samples, 154 had one or more additional samples taken during the first 48 h after baseline and these constitute the study population; a flowchart is included in the Supplementary material online, Appendix S1. The blood samples were centrifuged, plasma was separated and immediately stored frozen at −80 ∘ C until analysed. Creatinine (Roche Diagnostics, Basel, Switzerland) and CysC (Abbott Laboratories, Abbott Park, IL, USA) were analysed centrally. Creatinine levels were measured with Cobas 6000 automated analyzer (Roche Diagnostics) and CysC levels with Architect ci8200 automated analyzer (Abbott Laboratories).
We defined and staged AKI similarly to the KDIGO definition and staging (see Supplementary material online, Appendix S1). 4 For creatinine-based AKI (AKI crea ) ≥0.3 mg/dL or ≥50% increase in creatinine from baseline value was defined as stage 1, 100-199% increase as stage 2, and ≥200% increase or increase to ≥4.0 mg/dL in creatinine as stage 3 AKI. For AKI UO , UO <0.5 mL/kg/h for at least 6 h was defined as stage 1, <0.5 mL/kg/h for at least 12 h as stage 2, and <0.3 mL/kg/h for at least 24 h or anuria (defined as UO <50 mL/12 h or <100 mL/24 h) for at least 12 h as stage 3 AKI. Assessment of AKI crea was based on creatinine levels from baseline until 48 h, and the highest increase within this time was used for staging. AKI UO was staged by the lowest UO for a time interval within the first 24 h. For AKI CysC , a similar definition was used as for AKI crea : ≥0.3 mg/L or ≥50% increase from baseline as stage 1, 100-199% increase as stage 2, and ≥200% increase as stage 3 AKI CysC . 11, 12, 19, 20 Renal replacement therapy (RRT) was not included in AKI stage 3 criteria unless stated otherwise.
The primary endpoint of interest was 90-day all-cause mortality. Two patients had missing follow-up data after hospital discharge. The CardShock study was approved by local ethics committees at the participating centres (see Supplementary material online for details, Appendix S1) and conducted in accordance with the Declaration of Helsinki.
Statistical analyses
Results are presented as numbers and percentages for categorical variables, the mean with standard deviation or the median with interquartile range for continuous variables, as appropriate. Group comparisons were performed with Fisher's exact or chi-square test for categorical, Mantel-Haenszel trend test for ordinal, and t-test or Mann-Whitney U test for continuous variables, as appropriate. We examined the 90-day survival with Kaplan-Meier curves and performed group comparisons with log-rank test. For assessment of independent predictors of AKI, we used forward and backward selection of variables in logistic regression to calculate likelihood ratios, with significance <0.05 for inclusion and >0.1 for elimination; the final model was further adjusted for age and estimated glomerular filtration rate (eGFR) at baseline. We tested the independent association of AKI with 90-day mortality with logistic regression; multiple analyses were performed with different variable sets including CardShock risk score (see Supplementary material online, Appendix S1, for details) as a continuous variable 18 as well as gender and baseline SBP. The additive value of a variable in mortality prediction was assessed via the likelihood ratio test for nested models. Discriminative capability was assessed by the area under receiver operating curve (AUC). AUC comparisons were performed with DeLong method. We used linear mixed modelling to assess differences in haemodynamic measurements between groups over time.
Odds ratios (ORs) are shown with 95% confidence intervals (CIs). We considered P-values <0.05 as statistically significant. We performed statistical analyses with IBM SPSS Statistics, version 24.0 (IBM Corp, Armonk, NY, USA), and MedCalc Statistical Software, version 17.1 (MedCalc Software bvba, Ostend, Belgium). Venn diagram was drawn with eulerAPE.
Results
Baseline characteristics of the study patients (n = 154) are shown in Table 1 . In brief, mean age was 66 ± 12 years and 74% were men. Median creatinine was 1.12 (0.87-1.54) mg/dL, eGFR 64 (43-87) mL/min/1.73 m 2 and CysC 1.19 (0.90-1.69) mg/L. Acute coronary syndrome was the aetiology of CS in 81% of patients, and 76% underwent coronary angiography within 72 h before and 12 h after baseline. All-cause 90-day mortality was 38%.
The incidences of AKI stages according to the different definitions are shown in Figure 1a . Comparison of patient characteristics between those with and without AKI crea are shown in Table 1 ; for AKI CysC and AKI UO , see the Supplementary material online, Table  S1 . Using the KDIGO criteria for creatinine and UO, 31% developed AKI crea and 50% AKI UO . AKI CysC was observed in 33% of patients. In patients who developed AKI crea , 74% fulfilled the criteria during the first 24 h and 26% (12/47) between 24 to 48 h from baseline. As shown in Figure 1b , the different definitions of AKI were not entirely concordant; half of the AKI UO patients had no AKI crea or AKI CysC .
Renal replacement therapy was initiated within the first 48 h in 16 patients. Almost all of these patients (94%) had AKI UO , of which 80% had AKI UO stage ≥2, whereas 9 (56%) had AKI crea and 10 (63%) AKI CysC . Continuous RRT was used in nine patients and seven received intermittent haemodialysis either with or without ultrafiltration. Isolated ultrafiltration was used in five patients. 
Renal function, AKI crea , and mortality
Urine output and mortality
AKI UO was not independently associated with death at 90 days ( Table 2 ) and had no additive value in 90-day mortality prediction compared with AKI crea alone ( 2 = 0.843, P = 0.4 for comparison of nested models). AKI UO stages 2 and 3 were associated with increased rates of death ( Figure 2b ) and remained independently predictive of poor outcome after adjustment for gender, SBP and the CardShock risk score. However, stage 1 AKI UO (<0.5 mL/kg/h for 6 h) was not related to higher mortality ( Figure 2b) .
We explored a stricter UO threshold (i.e. UO <0.3 mL/kg/h for 6 h) previously used in the critically ill and found it to perform better in predicting 90-day mortality. This threshold showed better discriminative capability for death at 90 days than <0.5 mL/kg/h for 6 h, and combining UO <0.3 mL/kg/h 6 h with AKI crea improved 90-day mortality prediction compared with AKI crea alone ( Figure  2d and Supplementary material online, Table S2 ; 2 = 7.652, P = 0.006 for comparison of nested models). AKI UO with the stricter threshold also retained an independent association with 90-day mortality after multivariable adjustment (OR 3.6, 95% CI 1.4-9.3) ( Table 2 ).
Factors associated with development of AKI crea and AKI UO
Lower baseline arterial pH and previous use of diuretics were independently associated with higher incidence of AKI crea whereas lower baseline eGFR was an independent predictor of AKI UO . Whereas use of intravenous furosemide during the first 24 h correlated positively with cumulative 24 h UO, no association with AKI UO existed; instead, it was independently associated with higher incidence of AKI crea when added to the multivariable model of baseline variables. The only baseline variable that independently predicted the development of AKI UO was lower eGFR. Previous use of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers was not associated with increased incidence of AKI. Among those who underwent coronary angiography within 72 h before and 24 h after baseline, the amount of contrast media volume was positively associated with AKI UO , but not AKI crea .
Of note, use of dopamine within the first 24 h was not associated with development of AKI. In addition, the amount of administered fluid during the first 24 h correlated neither with the cumulative 24 h UO nor development of AKI UO . Figure 3 shows the incidences of AKI crea in haemodynamic measurement strata as well as the evolution of CVP, mean arterial pressure (MAP) and CI over time in patients with and without AKI; for AKI UO , see the Supplementary material online, Figure S1 . The highest CVP and lowest CI and MAP categories were associated with the highest incidence of AKI crea and AKI UO . Analogously, higher levels of CVP and lower MAP and CI were associated with both AKI crea and AKI UO (P < 0.5 for all pooled between-group comparisons). In addition, higher AKI crea stage and lower UO were associated with higher CVP and lower MAP and CI (see Supplementary material online, Figure S2) (Figure 1a) , and AKI CysC stages 2-3 were seen only in a few patients. Increasing AKI CysC stage was associated with a stepwise increase in mortality rates (Figure 2c) . Furthermore, AKI CysC showed an independent association with increased 90-day mortality after adjustment for gender, SBP and the CardShock risk score (OR 2.5, 95% CI 1.1-6.1, P = 0.04). 
Haemodynamic alterations in relation to the development of acute kidney injury
Discussion
This is the first study to prospectively evaluate AKI by contemporary KDIGO definitions in patients with CS, and also to describe AKI definitions using CysC. We found AKI to occur in more than one-third of the patients and to be associated with poor prognosis. However, the different AKI definitions were not entirely concordant. The AKI crea definition had a strong association with increased mortality. In contrast, AKI UO in prognostication, we propose a more stringent cut-off of <0.3 mL/kg/h for 6 h, which appeared useful in mortality prediction. Acute kidney injury was associated with haemodynamic alterations reflecting persistent venous congestion and hypoperfusion.
AKI crea criteria and mortality prediction
While AKI in hospitalized patients or the critically ill has been well studied, there is insufficient knowledge on AKI in the setting of CS. There are no previous data on current KDIGO AKI criteria Figure 3 Incidence of acute kidney injury defined by KDIGO creatinine criteria (AKI crea ) in haemodynamic measurement strata (upper panels), and the evolution of haemodynamic alterations over time (lower panels) in no-AKI crea and AKI crea patients. In the upper panels, P-values for trend for the association between AKI incidence and haemodynamic measurement strata are shown in each time interval. In the lower panels, lines represent the mean values with 95% confidence intervals of haemodynamic measurements within the time intervals. In the lower panels, P < 0.05 for all between-group comparisons and P = NS for all time-by-group interactions. CI, cardiac index; CVP, central venous pressure; MAP, mean arterial pressure.
in patients with CS. The most recent report, a single-centre substudy of the IABP-SHOCK II trial, used only stage 1 creatinine criteria for definition of AKI. 21 Two other single-centre studies on AKI in CS had specific inclusion and/or exclusion criteria and used heterogeneous definitions of AKI. 22, 23 Thus, findings in the previous studies of CS are not directly comparable with those of our study. However, our study confirmed two key messages: the high incidence of AKI crea in CS and its association with a notably poor prognosis. The results of our study are also similar to other studies using KDIGO definitions in unselected critically ill patient populations. 6, 16, 17 Nevertheless, it must be emphasized that mortality in CS patients is consistently higher than in the overall unselected intensive care unit (ICU) population. Mortality rates in CS are further increased by AKI crea , which was a strong and independent predictor of death at 90 days.
Urine output as a criterion for acute kidney injury and in mortality prediction
In this study, half of the patients fulfilled the AKI UO criteria compared with only one-third having AKI crea . The UO criterion has previously been found to increase the sensitivity for AKI . detection and AKI UO to be more frequent than AKI by creatinine criteria. 24 -26 Data on the utility and concordance of the current KDIGO definitions of AKI UO are, however, conflicting. While the FINNAKI study including Finnish ICU patients showed severe oliguria to be highly predictive of AKI crea , 8 some studies have shown that many patients with oliguria do not develop AKI crea . 26, 27 The concordance in the frequency and staging of AKI between the definitions was even weaker in our study; a rather large proportion of patients with AKI UO did not develop AKI crea and vice versa. Consequently, the current UO threshold in the KDIGO guidelines had a modest association with development of AKI crea . All in all, concordance between AKI UO and AKI crea seems to be inconsistent. 8, 26 -28 In our study, only stage ≥2 AKI UO , i.e. a longer duration (at least 12 h) of UO <0.5 mL/kg/h, was independently associated with increased mortality. Although some studies have found the UO criteria to perform well in mortality prediction, our data do not fully support this view. For the 6 h measurement period, we tested a previously suggested cut-off of <0.3 mL/kg/h and found it to be more appropriate for mortality prediction 7 . This cut-off was also more specific for and had a stronger association with incidence of AKI crea . In addition, we found that combining this cut-off with AKI crea provided additive value in mortality prediction and patients fulfilling both AKI crea and UO <0.3 mL/kg/h for 6 h criteria had the highest mortality.
Initial resuscitation with large amounts of fluids in the critically ill and diuretic use may obscure the detection of AKI UO by affecting diuresis. Whereas intravenous furosemide positively correlated with urinary volume, no association with AKI UO existed. Instead, intravenous furosemide was associated with increased incidence of AKI crea . Furthermore, the amount of administered fluid did not correlate with urinary volume. As UO is a vital component in monitoring kidney function and an easily measurable parameter, and despite its shortcomings, its inclusion instead of omission in the AKI definition is justifiable and the stricter UO cut-off for AKI detection seems preferable in CS.
Haemodynamic alterations in relation to AKI crea and urine output
This is the first study, to our knowledge, to assess serial haemodynamic measurements in CS in relation to AKI and UO in particular. Not only persistent venous congestion, as measured by an increase in CVP, but also arterial and organ hypoperfusion reflected by a lower arterial pressure and CI were shown to associate with both AKI incidence and severity. Indeed, several studies have emphasized the role of venous congestion in the development of worsening renal function in cardiovascular diseases. 29, 30 Then again, while low cardiac output has been shown to associate with worsening renal failure in many settings, studies by Mullens et al. 30 and, more recently, Hanberg et al. 31 have, however, shown that the role of CI in AHF is limited. The effect of hypoperfusion caused by a severe derangement in cardiac output and low arterial pressure exceeding the autoregulation capacity of the kidney has probably a more relevant role in CS than in less severe forms of AHF. The backward failure and severe neurohormonal activation caused by CS can lead to a significant increase in venous congestion as well; venous congestion is further aggravated by fluid administration used to counter hypotension and hypoperfusion. In addition to the haemodynamic derangements, the pronounced inflammatory response and neurohormonal activation further exacerbate renal injury and dysfunction. Furthermore, use of nephrotoxic agents, such as contrast media and diuretics, in remarkably labile conditions may produce excessive deleterious effects.
In addition to AKI crea , also AKI UO was associated with such haemodynamic alterations. However, the effect was more pronounced in or seemingly driven by a more significant reduction in UO as reflected by the difference between groups 0.3-0.5 and <0.3 mL/kg/h for 6 h, thus advocating for the assimilation of a stricter cut-off to be used as AKI UO definition in CS.
Cystatin C as a marker of acute kidney injury
Serum CysC, an alternative to creatinine as a filtration marker and a risk stratification tool, 9 has been studied for detection and prognostication of AKI in AHF, critically ill, and surgical patients. 10, 11, 19, 32 10 and to be at least as accurate or even superior in estimation to acute changes in eGFR, 33 and the independence of CysC level from height, gender, age, and muscle mass is advantageous. CysC-based AKI definition might be particularly useful in the elderly and in patients with changes in creatinine metabolism or muscle mass due to catabolic critical illness for example. A recent study in an unselected ICU population reported that AKI CysC was slightly better in short-term mortality prediction than creatinine-based definitions of RIFLE, AKIN, or KDIGO.
12 While our study showed that AKI CysC was independently associated with mortality, it provided no clear advantage over AKI crea . Although the incidence of AKI was similar using CysC and creatinine definitions, the two markers identified AKI patient cohorts with differences in AKI stages, which is in line with a previous study on AHF patients. 19 While the cut-off of 0.3 mg/L increase has been used in several cohorts to define AKI CysC , 19, 20, 32 definitions for AKI CysC stages 2 and 3 have not been well established. All in all, CysC seems to be a feasible alternative as an AKI marker but further studies are warranted.
Limitations
There are some limitations that should be acknowledged. First, we assessed AKI only for the first 48 h. However, most of AKI in the critically ill occur within the first day, 8 and also in our study 74% of patients developed AKI within the first 24 h. Furthermore, many AKI patients died already within 48 h. Second, UO was not recorded hourly but with fixed time intervals of 6 h. However, measuring UO in fixed intervals has been suggested to be more sensitive and more practical than assessing consecutive hourly measurements facilitating the application of the criteria. 25 Third, no data on creatinine prior to index hospitalization for CS was available. On the other hand, the European Renal Best Practice position statement, for example, recommends using baseline rather than historical creatinine values or a calculated value based on an assumed GFR of 75 mL/min. 5 No information on diabetes type (I or II), time since diagnosis, or need for insulin treatment was available. Finally, the assessment and detection of kidney function with plasma and urine biomarkers were not necessarily obtained simultaneously with haemodynamic measurements and derangements. However, the changes in kidney function and haemodynamic parameters occur in a continuum over time rather than at a particular time point. Our results show a marked association between haemodynamic derangements persisting from before the detection of AKI until its detection and even thereafter.
Conclusion
Acute kidney injury is frequent in CS, and AKI crea is strongly associated with increased 90-day mortality. The current UO-based KDIGO AKI definition was rather liberal compared with AKI crea and not independently associated with increased mortality. Based on the current study, we propose a more stringent threshold, <0.3 mL/kg/h for 6 h, to improve mortality prediction. AKI crea and AKI UO were associated with haemodynamic alterations reflecting venous congestion and hypoperfusion. Cystatin C may be used as an alternative to creatinine for AKI definition and mortality prediction in CS.
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